Center for Medical Ethics and Health Policy Staff Publications

Publication Date

1-1-2025

Journal

WIREs Nanomedicine and Nanobiotechnology

DOI

10.1002/wnan.70020

PMID

40458962

PMCID

PMC12131291

PubMedCentral® Posted Date

6-3-2025

PubMedCentral® Full Text Version

Post-print

Abstract

The Nanotechnology Characterization Laboratory (NCL) is a US federally funded resource providing characterization and expertise to the cancer nanomedicine research community. Founded as a formal partnership among the US National Cancer Institute (NCI), the US Food and Drug Administration (FDA), and the US National Institute of Standards and Technology (NIST), the NCL has spent two decades developing a one-of-a-kind service with broad multidisciplinary expertise to meet the needs of a rapidly evolving drug development field. To mark the 20th anniversary of the lab's founding, the NCL hosted a symposium to highlight the achievements of the cancer nanomedicine field, showcase novel, next-generation nanotechnology research, and discuss future priorities to enable continued growth in combating cancer and the complexities associated with treating a disease that continues to take millions of lives annually. The discussion topics from this event are summarized.

Keywords

United States, Humans, National Cancer Institute (U.S.), Neoplasms, Nanomedicine, Nanotechnology

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.